All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-03-15T17:11:19.000Z

Effect of allo-HSCT and BM fibrosis regression on OS in patients with MF

Mar 15, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in myelofibrosis.

Bookmark this article

Patients diagnosed with intermediate-2 and high-risk myelofibrosis (MF) are currently only able to achieve curative therapy through allogeneic hematopoietic stem cell transplantation (allo-HSCT).1 Gandhi1 presented a study investigating the impact of pre-allo-HSCT splenomegaly, splenic irradiation, and pre- and post-HSCT marrow fibrosis on overall survival (OS) at the 2023 Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR, and we are pleased to summarize the key findings from the study below.

The MPN Hub recently published a related article summarizing the association between changes in bone marrow fibrosis and clinical efficacy of MF treatments here.

Study design

A total of 34 patients diagnosed with either primary or secondary MF and who underwent allo-HSCT between 2005 and 2021 were enrolled in the study. Baseline patient characteristics are shown in Table 1.

Table 1. Baseline patient characteristics*

Characteristic, % (unless otherwise stated)

N = 34

Age at allo-HSCT (range), years

62 (4273)

KPS

              90

32.4

              80

58.8

              70

8.8

Primary MF

61.8

Secondary MF

38.2

DIPSS score

              Intermediate-1 risk

5.9

              Intermediate-2 risk

58.9

              High risk

29.4

              N/A

5.9

JAK2 mutation

              Yes

58.9

              No

29.4

              N/A

11.8

Pre-allo-HSCT spleen size

              ≤20 cm

58.8

              >20 cm

41.2

Pre-allo-HSCT splenic irradiation

              Yes

44.1

              No

55.9

Pre-allo-HSCT marrow fibrosis

              Grade 1

14.7

              Grade 2

23.5

              Grade 3

61.8

Conditioning regimen

              MAC

23.5

              RIC

64.7

              NMA

11.8

allo-HSCT, allogeneic hematopoietic stem cell transplant; DIPSS, Dynamic International
Prognostic Scoring System; KPS, Karnofsky performance score; MAC, myeloablative conditioning;
MF, myelofibrosis; NMA, non-myeloablative conditioning; RIC, reduced-intensity conditioning.
*Adapted from Gandhi.1

Results

The median follow-up for patients was 47 months. Median OS was not reached; however, the 1-year overall OS rate was 58.8% (95% confidence interval [Cl], 44–78)2 and both reduced intensity conditioning and myeloablative conditioning regimens yielded similar 1-year OS rates (Figure 1).

Figure 1. 1-year OS rates for conditioning regimens* 

MAC, myeloablative conditioning; NMA, non-myeloablative conditioning; OS, overall survival; RIC, reduced-intensity conditioning.
*Adapted from Gandhi.1

  • Neutrophil and platelet engraftment took a median of 17 and 31 days, respectively.
  • Patients with a spleen size >20 cm and those undergoing splenic irradiation experienced delayed neutrophil engraftment (hazard ratio [HR], 0.44; p = 0.033; and HR, 0.37; p = 0.012, respectively) and delayed platelet engraftment (HR, 0.55; p = 0.153; and HR, 0.38; p = 0.026, respectively).
  • The median dose of CD34 cells administered to patients was 5.9 × 106 cells/kg.2
  • Higher CD34 cell doses were associated with faster neutrophil engraftment (HR, 1.42 per 106 cells; p < 0.001) but had no effect on platelet engraftment or OS.
  • 19 patients experienced Grade ≥2 acute graft-versus-host disease (GvHD),2 with a median onset of 54 days after transplantation.
  • 15 patients experienced chronic GvHD,2 with a median onset of 8 months after transplantation (Table 2).

Table 2. Rates of post-HSCT GvHD*

Characteristic, %

N = 34

Acute GvHD

              None

32.3

              Grade 1

8.8

              Grade 2

17.6

              Grade 3–4

38.2

              Engraftment syndrome

2.9

Chronic GvHD

              None

55.9

              Limited

14.7

              Extensive

26.5

              Unknown extent

2.9

GvHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation.
*Adapted from Gandhi.1

Bone marrow fibrosis grade results were available in 24 patients. Over 1 year, 17 patients experienced bone marrow fibrosis regression, whereas 7 patients experienced none (Figure 2).1,2 Patients with Grade ≥2 acute GvHD were less likely to have bone marrow regression after 1 year (p = 0.292).

Figure 2. Number of patients experiencing bone marrow fibrosis regression in 1 year* 

*Adapted from Gandhi.1,2

Predictors of any cause mortality were identified as:

  • Bone marrow fibrosis regression (HR, 0.20; 95% CI, 0.04–1.08; p = 0.061)
  • Grade ≥2 acute GvHD (HR, 4.42; 95% CI, 1.22–16.08; p = 0.024)
  • Secondary MF (HR, 3.16; 95% CI, 1.16–8.61; p = 0.024)

Conclusion

The results from this study indicate a strong correlation between acute GvHD, lack of marrow fibrosis regression, and increased risk of patient mortality. Further investigation of the potential for novel treatment strategies such as T-cell depletion to rapidly remodel the bone marrow niche, thus improving OS in MF is warranted.

  1. Gandhi A. Overall survival in myelofibrosis treated with allogeneic hematopoietic cell transplant is impacted by reversal of marrow fibrosis: A single institution experience from Oregon Health & Science University. Poster #156. 2023 Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR; Feb 16, 2023; Orlando, US.
  2. Gandhi A, Guitierrez A, Kaempf A, et al. Overall survival in myelofibrosis treated with allogeneic hematopoietic cell transplant is impacted by reversal of marrow fibrosis: A single institution experience from Oregon Health & Science University. Abstract #156. Presented at: 2023 Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR; Feb 16, 2023; Orlando, US.

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox